@article{JTD19447,
author = {Guirong Wang and Shuqi Wang and Guanglu Jiang and Yuhong Fu and Yuanyuan Shang and Hairong Huang},
title = {Incremental cost-effectiveness of the second Xpert MTB/RIF assay to detect Mycobacterium tuberculosis},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {3},
year = {2018},
keywords = {},
abstract = {Background: Due to the non-homogeneity of specimens collected from tuberculosis (TB) suspects, repeated Xpert MTB/RIF (Xpert) may have potential clinical benefits. Incremental cost-effectiveness was analyzed for the second Xpert assay to detect Mycobacterium tuberculosis (Mtb) and rifampicin (RIF) resistance.
Methods: Specimens were collected from 1,063 pulmonary TB (PTB) and 398 extrapulmonary TB (EPTB) suspects, who had two Xpert tests sequentially within one week. The specimens were subjected to smear, culture, Xpert and drug susceptibility testing. Incremental cost-effectiveness of the serial Xpert assays was evaluated.
Results: Among 813 Xpert-positive TB patients, 755 (92.87%) were identified by the first assay whereas the additional 58 (7.13%) were identified by the second assay. The second Xpert assay had higher incremental yield for smear-negative than for smear-positive specimens (12.07% vs. 1.84%, P},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/19447}
}